Business Context and Reporting Period
This Form 6-K filing by GSK plc (Commission File Number 001-15170) reports a transaction in the company's own shares. The filing covers the month of July 2025, specifically detailing share repurchases executed on July 3, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than general financial performance metrics such as revenue or profit.
- Shares Purchased: 491,972 ordinary shares of 31½ pence each.
- Transaction Date: July 3, 2025.
- Price Range: Lowest price paid was 1,380.50p; highest price paid was 1,411.00p.
- Volume-Weighted Average Price (VWAP): 1,396.15p.
- Trading Venue: London Stock Exchange (XLON). No purchases were made on CBOE Europe (CHIX or BATE).
- Treasury Shares Held: Following this purchase, GSK holds 227,628,298 ordinary shares in treasury.
- Shares in Issue: 4,087,741,901 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 5.57% of total voting rights.
Material Changes and Program Status
This purchase is part of GSK's existing buyback programme, executed pursuant to a non-discretionary agreement with broker Merrill Lynch International entered into on June 4, 2025.
- Cumulative Activity: Since June 4, 2025, the Company has purchased a total of 9,493,915 ordinary shares.
- Share Count Impact: The transaction reduced the number of shares in issue and increased the treasury share count, resulting in the 5.57% voting rights attribution noted above.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, revenue outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in GSK's 2024 Annual Report on Form 20-F and Q1 2025 Results.
Important Facts for Investor Verification
- Verify the total number of shares in issue (4,087,741,901) for calculating ownership percentages under Disclosure Guidance and Transparency Rules.
- Confirm the percentage of voting rights held in treasury (5.57%) to assess potential dilution or voting power dynamics.
- Note that the buyback is executed via a non-discretionary agreement with Merrill Lynch International, implying automated trading within set parameters.
- Review the cumulative buyback volume (9,493,915 shares since June 4) to gauge the pace of capital return relative to the total programme size.